Clearance Summary
Atellica® CH Diazo Direct Bilirubin (D_DBil) received FDA 510(k) clearance under submission number K223078, sponsored by Siemens Healthcare Diagnostics, Inc.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Clinical Chemistry review panel. The statutory decision date of record is 2023-06-12.
- Submission: K223078
- Applicant / Sponsor: Siemens Healthcare Diagnostics, Inc.
- Clearance pathway: Traditional
- Review panel: Clinical Chemistry
- Device class: Class II
- Regulation citation: 21 CFR 862.1110
- Decision date: 2023-06-12
Classification & Regulation
This clearance is catalogued under FDA product code CIG and 21 CFR 862.1110, within the Clinical Chemistry review panel as a Class II device.